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Organic nitrates represent a class of drugs which are clinically used for treatment of ischemic symptoms of angina as well as for
congestive heart failure based on the idea to overcome the impaired NO bioavailability by “NO” replacement therapy. The present
paper is focused on parallels between diabetes mellitus and nitrate tolerance, and aims to discuss the mechanisms underlying
nitrate resistance in the setting of diabetes. Since oxidative stress was identiﬁed as an important factor in the development of
tolerance to organic nitrates, but also represents a hallmark of diabetic complications, this may represent a common principle
for both disorders where therapeutic intervention should start. This paper examines the evidence supporting the hypothesis that
pentaerithrityl tetranitrate may represent a nitrate for treatment of ischemia in diabetic patients. This evidence is based on the
considerations of parallels between diabetes mellitus and nitrate tolerance as well as on preliminary data from experimental
diabetes studies.
1.Introduction
1.1. Clinical and Economical Importance of Diabetes Mellitus.
According to an estimation of the World Health Organi-
zation (WHO) in November 2009, more than 220 million
people worldwide suﬀer from diabetes mellitus, a ﬁgure that
will probably double by the year 2030. The economic and
human costs of this disease are devastating. WHO estimates
that in the period 2006–2015, China will lose $558 billion
in foregone national income due to heart disease, stroke,
and diabetes alone. The total cost of diabetes in the United
States in 2002 was $132 billion. According to the statistics
of the NIH in 2007, 23 million Americans had diabetes, and
the estimated lifetime risk for Americans born in 2000 to
develop diabetes is 1 in 3. In adults, diabetes is the most
commoncauseofblindness,nontraumaticamputations,and
end-stage renal disease as well as the sixth most common
cause of death. In Germany, every 19 minutes a person with
diabetes suﬀers a heart attack. With regard to these facts, it is
of high clinical and economical importance, but also in the
interest of the patients and their quality of life, to ﬁnd new
therapeutic options for the treatment of diabetes. Primarily,
this research should be focused on the treatment of the
metabolic disorder underlying diabetes to stop or slow down
its progression. But also the treatment of diabetes symptoms
and complications need to be addressed to improve the
quality of life and prognosis of diabetic patients. Yet only
limited knowledge exists about the pathogenesis, the cardio-
vascularconsequences,andthepreventionofthisdisease[1].
Recent data suggest that the cardiovascular complications
in diabetes mellitus are associated with oxidative stress
[2, 3], as previously shown for hypercholesterolemia and
arteriosclerosis [4, 5]. The sources of these reactive oxygen
and nitrogen species (RONS) have been identiﬁed to be
NADPH oxidases, mitochondria, xanthine oxidase, as well
as an uncoupled endothelial nitric oxide synthase (eNOS)
[6–8]. The present review will address the question whether
organic nitrates may be used for treatment of diabetic
patients, and if there are diﬀerences between the organic
nitrates being in clinical use at present.2 Experimental Diabetes Research
1.2. Biochemical and Metabolic Consequences of Diabetes
Mellitus. The relationship between diabetes and the result-
ing cardiovascular complications is complex, but damage
to the vascular endothelium obviously plays a major role
[9]. Chronic exposure of proteins from plasma and the
cell membrane to hyperglycemia leads to the attachment of
glucose molecules to proteins, a process known as nonen-
zymatic glycosylation. Subsequent slow reactions cause the
formation of advanced glycation end products (AGEs)
[10] known to inactivate nitric oxide (NO) and impair
endothelium-dependent vasodilation [11]. However, short-
term hyperglycemia leads to similar negative eﬀects on
vascular responses, suggesting that this is not the only
mechanism [12]. It was shown that hyperglycemia inhibits
eNOS-dependent NO formation in favour of superoxide
production, leading to an impaired endothelium-dependent
vasodilation [13]. Besides the formation of advanced gly-
cation end-products and diacylglycerol (DAG), the simul-
taneous increase in production of reactive oxygen species
(especially superoxide, O2
￿−) contributes to inhibition and
uncoupling of eNOS via depletion of BH4 (summarized in
Figure 1).Moreover,indiabeticpatients,ahigherproduction
of vasoconstrictive compounds, such as endothelin-1 and
angiotensin-II, has been observed. The increase in DAG and
angiotensin-II is a direct consequence of the activation of the
renin-angiotensin-aldosterone system (RAAS) in the setting
of diabetes [14], which is also closely related to endothelial
dysfunction [15, 16]. Since DAG is a potent activator of
the protein kinase C [17, 18] with subsequent activation of
the NADPH oxidase [19], RAAS-induced activation of this
superoxide source was demonstrated by clinical [20]a sw e l l
as animal experimental studies [21] .T h e r ei se v e ns o m e
evidence that suppression of the RAAS is able to prevent the
development or progression of diabetes mellitus type II in
hypertensive patients [22]. The events taking place during
activation of the RAAS are summarized in Figure 2.
Leukocyte inﬁltration into the vascular wall was
also dramatically increased. The increased concentrations
of cytokines and matrix metalloproteinases lead to a
decreased synthesis and increased degradation of collagen
in atherosclerotic plaques reducing the stability of the
ﬁbrous cover plate, ﬁnally causing plaque rupture, thrombus
formation, and myocardial infarction. In addition, the
thrombocytes in diabetic individuals are larger in size,
express more glycoprotein receptors on the surface, and
show more pronounced aggregation in response to diﬀerent
stimuli (for review see [23]). Patients with diabetes mellitus
have a 2- to 4-fold increased risk for infarction, and
the mechanistic basis for macrovascular complications is
progression of atherosclerosis. Endothelial dysfunction is
a hallmark in the early stage of diabetes mellitus type 1
and 2 [24]. Oxidative protein modiﬁcations such as 3-
nitrotyrosine formation [25], oxidative disruption of the
zinc-sulphur-cluster, and uncoupling of eNOS [26]a sw e l la s
increased levels of toxic aldehydes [27] are common features
of diabetes and may contribute to the observed disorders.
Ab r o a dv a r i e t yo fd i ﬀerent antioxidants have been demon-
strated to beneﬁcially inﬂuence diabetic complications
[27–30].
2.OrganicNitrates
2.1. Clinical Use of Organic Nitrates. Nitroglycerin (glyc-
eryl trinitrate) and the long-acting nitrates (isosorbide-
5-mononitrate [ISMN], isosorbide dinitrate [ISDN], and
pentaerithrityl tetranitrate [PETN]) have been used in
cardiovascular medicine for >100 years. Despite the fact that
the potential mechanisms for relief of myocardial ischemia
with nitrates are multiple and not yet fully understood
[32], nitrates are widely utilized for the various anginal
syndromes, and are also used in congestive heart failure
and in patients with left ventricular dysfunction [33, 34].
The nitrovasodilators are a group of drugs that result in the
formation of NO or a related species within vascular smooth
muscle cells [35]. Following the discovery of endothelium-
derived NO [36], the idea of NO being the active principle
of nitrates was very attractive to the scientiﬁc community,
and it led to the speculation that they may replace a
compromised endothelial NO production [37], such as in
patients with coronary heart disease. Nitrates also have
antiaggregatory eﬀects, and recent evidence conﬁrms that
these drugs decrease platelet aggregation and thrombosis
formation [38], although for nitroglycerin, an activation
of thrombocytes was described [39, 40]. This may play an
important role in the therapy of acute unstable myocardial
ischemia, including unstable angina and myocardial infarc-
tion. The hemodynamic eﬀects of nitrates were known for
a long time. They are primarily modulated by decreased
myocardial work that results from smaller cardiac chambers
thatoperatewithlowersystolicanddiastolicpressures.These
changes are secondary to a redistribution of the circulating
blood volume from cardiac tissue to the venous capacitance
system, with a decrease in venous return to the heart. The
eﬀects of nitrates on afterload as well as on arteries are also
useful for the decrease in myocardial oxygen consumption.
Considerable evidence supports a variety of mechanisms
whereby nitrates lead to increased coronary blood ﬂow,
including stenosis enlargement, epicardial coronary artery
dilation, improvement of endothelial dysfunction, enhanced
collateral size and ﬂow, and prevention or reversal of
coronary artery vasoconstriction [33].
2.2. Bioactivation of Organic Nitrates. There is a consensus
that the principle mechanism of organic nitrate-induced
smooth muscle relaxation is achieved via NO signalling
pathways, including activation of soluble guanylyl cyclase,
increase in cyclic GMP levels and activation of cyclic GMP-
dependent protein kinases, and/or cyclic nucleotide-gated
ion channels which was extensively reviewed [32]. Recently,
the organic nitrate-derived NO hypothesis was challenged
by two independent studies using state-of-the-art-methods
to detect nitrate-derived NO formation which showed a
huge discrepancy between nitroglycerin-derived NO and
NO-induced vasodilation [35, 41]. This, however, questions
the relevance of nitroglycerin-derived NO formation in
the clinically relevant concentration range whereas NO
was detected for ISMN and ISDN during vasodilation of
isolated aortic rings. For nitroglycerin, several bioactivatingExperimental Diabetes Research 3
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Figure 1: The scheme summarizes the simpliﬁed mechanisms underlying oxidative stress-induced endothelial dysfunction (and probably
nitrate resistance) in diabetes mellitus. It should be noted that the oxidative stress concept provides an explanation for a part of
diabetic complications and probably represents one important pathological pathway among several. Prevention of diabetic cardiovascular
complications by induction of the heme oxygenase antioxidant system. Key mediators of these beneﬁcial eﬀects are carbon monoxide (CO)
bilirubin,extracellularsuperoxidedismutase(ecSOD),couplingofendothelialNOsynthase(eNOS)bynormalizationoftetrahydrobiopterin
(H4B) levels, and decrease in superoxide levels. Adopted from Abraham and Kappas, Pharmacol. Rev. 2008 [31].
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Figure 2:Sequenceofeventsduringactivationoftherenin-angiotensin-aldosteronesystem(RAAS)inthesettingofhyperglycemia(diabetes
mellitus type 1 and 2) or nitrate tolerance. Some therapeutic and experimental interventions are also shown. AT-II: angiotensin-II; DAG:
diacylglycerol; PKC: protein kinase C; Thr495 P-eNOS: threonine495-phosphorylated endothelial NO synthase; NO: nitric oxide; O2
￿−:
superoxide; ONOO−: peroxynitrite; PGIS: prostacyclin.
systems have been proposed during the last decades includ-
ing xanthine oxidoreductase, glutathione-S-transferases, and
cytochrome P450 enzymes (for review see [32, 34]). It
should be noted that these reports on nitroglycerin-derived
NO formation were based on high suprapharmacological
concentrations (>10μM) of the nitrate. Mononitrates and
dinitrates have been reported to be mainly bioactivated
by cytochrome P450 enzymes. In 2002, the mitochondrial
aldehyde dehydrogenase (ALDH-2) was identiﬁed as an
organic nitrate bioactivating enzyme [42]. This so-called
nitrate reductase activity denitrates nitroglycerin to its 1,2-
glycerol dinitrate metabolite and nitrite. This reaction relies4 Experimental Diabetes Research
on reduced thiols at the active site of the enzyme and on the
presence of reduced dithiols as the electron source. During
bioconversion of nitroglycerin, but also in the presence of
reactive oxygen and nitrogen species, the active site thiols of
ALDH-2 are oxidized, and the enzyme loses its activity [43].
Interestingly, ALDH-2 bioactivates nitroglycerin, PETN, and
its trinitrate metabolite PETriN but not ISMN and ISDN
[44], which could explain the diﬀerent potency of these
nitrates.
2.3. Clinical Tolerance, Endothelial Dysfunction, and Dif-
ferences between Organic Nitrates. Tolerance and cross-
tolerance to endothelium-dependent vasodilators (endothe-
lial dysfunction) are a major limitation for chronic nitrate
treatment.Clinicaltoleranceandcross-tolerancemayinvolve
counterregulatory mechanisms (pseudotolerance) including
release of catecholamines and activation of the renin-
angiotensin-aldosterone system (RAAS) making these phe-
nomena even more complicated [32]. The ﬁrst evidence
for an involvement of the renin-angiotensin-aldosterone-
system (RAAS) in GTN-induced nitrate tolerance came
from observations that long-term inhibition of angiotensin-
converting enzyme improves nitrate tolerance in dogs [45,
46]. Additional studies showed that AT1-receptor blockade
and ACE inhibition positively inﬂuence the development of
tolerance,anditwashypothesizedthatthisprotectiveeﬀectis
mediated via inhibition of NADPH oxidase-dependent ROS
formation [45, 47–53]. In contrast, there is a limited number
of studies reporting on lack of eﬀect of ACE inhibitors
and AT1-receptor blockers on nitrate tolerance [54–56]a n d
nitrate-induced oxidative stress [57]. Downstream to the
RAAS system is the protein kinase C (PKC), which was also
identiﬁed as an important constituent in the development
and maintenance of GTN-induced nitrate tolerance [58–60].
Moreover, it was demonstrated that GTN-induced activation
of PKC mediates late preconditioning, a protective eﬀect
which is probably based on initial ROS formation and
mild oxidative damage [61]. The contribution of NAD(P)H
oxidases to ROS production and oxidative damage in
response to GTN therapy was established by a number of
independent studies [62–64]. Nevertheless, NADPH oxidase,
as a source of ROS formation in the setting of tolerance,
was questioned since DPI, an unspeciﬁc inhibitor of ﬂavin-
dependent oxidoreductases, could not prevent the impaired
responsetoGTNintolerantvesselsexvivo[65].Insummary,
the majority of previous work supports the contribution of
the RAAS, PKC, and NADPH oxidase to the development
of nitrate tolerance (the sequence of events is provided in
Figure 2) although some studies neglect the importance of
this pathway.
Tolerance and/or endothelial dysfunction have been
observed in response to chronic treatment with nitroglycerin
[66, 67], ISMN [68], and ISDN [69] (studies before 1990
reviewed in [70]) whereas no tolerance phenomena or
markers such as oxidative stress were observed for long-term
administration of PETN [67, 71]. These reports indicate that
tolerance development is uniform to all organic nitrates if
applied in clinically eﬀective dosage for longer periods of
time. A remarkable exception seems to be PETN [72]. Some
of these eﬀects are related to special pharmacokinetics of
PETN [73, 74], but, upon chronic administration, PETN
also induces antioxidant pathways at the genomic level
and cardioprotective genes (e.g., Apex1 and NFAT5) [75].
Amongtheseinducedantioxidantgenesarehemeoxygenase-
1 (HO-1) and ferritin [76], both possessing highly protective
properties. There is good experimental evidence that at least
part of the beneﬁcial proﬁle of long-term PETN treatment
is based on activation of the heme oxygenase-1/ferritin
system [77] and preliminary data in heme oxygenase-1
knockout mice support these previous ﬁndings. According
to recent, unpublished data from our laboratory, PETN
even acts diﬀerently at the puriﬁed ALDH-2, preventing
inactivation of this nitrate reductase. Since ALDH-2, beyond
bioactivating organic nitrates, was recently identiﬁed as an
important protective enzyme, preventing ischemic damage
in experimental myocardial infarction [78], the conservation
of the enzymatic activity of ALDH-2 by an organic nitrate
may be of great importance for long-term treatment of
patients with ischemic heart disease. Nitroglycerin not only
inactivates ALDH-2 but also downregulates the enzyme at
the protein level [79]. More diﬀerences between organic
nitrates in clinical use were recently discussed in detail
[80]. The diﬀerences between nitroglycerin and PETN are
summarized in Figure 3.
2.4. Nitrate Tolerance and the “Oxidative Stress Concept”.
The “oxidative stress concept” in the setting of nitrate
tolerance was established by Munzel and colleagues [82]
and reﬁned during the last couple of years [66, 83].
In essence, the concept consists of increased superoxide
formation in response to nitrate treatment which decreases
NO bioavailability, leads to peroxynitrite formation, NOS
uncoupling, and impairs NO/cyclic GMP signalling [66].
Moreover, oxidative inhibition of prostacyclin synthase [84]
as well as mitochondrial ALDH activity [85]m a yp r e s e n t
other key events in the development of nitrate tolerance.
Previously, the vascular NADH oxidase was considered as
the most important source of reactive oxygen species (ROS)
in the setting of nitrate tolerance [32]. Today this concept
has been extended to induction of mitochondrial oxidative
stress by nitroglycerin treatment [83, 86] and a crosstalk
between mitochondrial ROS with NADPH oxidases in the
cytoplasmic membrane [87]. Induction of oxidative stress
was also described for ISMN in experimental hyperten-
sion [88], and indirect evidence was presented recently
by demonstrating that the antioxidant vitamin C reverses
ISMN-inducedendothelialdysfunctioninhealthyvolunteers
[68]. However, until now, there is no direct proof for
induction of oxidative stress by ISMN from clinical trials
[89]. For ISDN, increased activation of NADPH oxidase was
demonstrated in experimental MI as well as the adverse
eﬀectsofthenitrateonthefunctionofendothelialprogenitor
cells[90]althoughpreviousworkbyKeimeretal.revealedno
induction of oxidative stress under ISDN or PETN therapy
in healthy volunteers [91]. Indirect evidence for a role of
oxidative stress in ISDN therapy comes from the highly
beneﬁcial eﬀects of hydralazine combination therapy [92]
since hydralazine is a powerful antioxidant [93] and has beenExperimental Diabetes Research 5
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Figure 3: Vasodilation by nitroglycerin (NTG) and PETN: bioactivation to NO or a related species with subsequent activation of soluble
guanylyl cyclase (sGC) and smooth muscle relaxation. Mechanisms underlying induction of vascular dysfunction by nitroglycerin and
prevention of these adverse eﬀects by activation of antioxidant, protective pathways by PETN: nitroglycerin induces mitochondrial and
NADPH oxidase-dependent oxidative stress leading to uncoupling of eNOS and desensitization of sGC. PETN prevents these harmful events
by induction of the antioxidant principle heme oxygenase and ferritin as well as others which are not shown here. Adopted from Gori et al.,
Arzneimitteltherapie 2008 [81].
demonstrated to prevent nitroglycerin-induced tolerance
[62]. Related to these observations on adverse eﬀects of
nitrate therapy, Nakamura et al. presented evidence that
long-term nitrate therapy increases cardiovascular mortality
based on a retrospective analysis using databases from two
large-scale postinfarction studies [94]. It should be noted
that this analysis did not distinguish between diﬀerent
nitrates although there is increasing evidence that organic
nitrates should not be treated as a homogenous class of
compounds. Moreover, it is important to keep in mind that
PETN did not share the adverse eﬀects of the other nitrates
since it was devoid of tolerance [67, 71, 74], induction of
oxidative stress [71, 90] and downregulation of protective
genes [75, 77]. Recent data has shown that nitroglycerin
and PETN, although both considered as NO donors, exert
completely opposite eﬀects with respect to gene regulation:
PETN in vivo treatment induced cardioprotective genes
(e.g., Apex1 and NFAT5) whereas nitroglycerin in vivo
administration induced cardiotoxic genes (e.g., Egr1, fos,
junD, and MITF) [75]. Another highly important property
ofPETNmaybetheinductionoftheextracellularsuperoxide
dismutase (ecSOD) [95] and glutathione peroxidase (GPx)
[96], two highly protective antioxidant proteins. These
experimental and clinical data on the beneﬁcial eﬀects
of PETN were recently supported by the double-blind,
placebo-controlled PENTA study conducted by Warnholtz
and colleagues with the main ﬁnding that chronic PETN
treatment does not induce endothelial dysfunction or
nitrate tolerance, but even improves GTN potency [97].
Relative changes in mean ﬂow volume and mean ﬂow
velocity upon ischemia increased in the PETN group versus
controls.6 Experimental Diabetes Research
3. Use of OrganicNitrates for Therapy of
DiabeticPatients
3.1. Nitrate Resistance and Diabetes. The endothelial dys-
function present in hypercholesterolemic, type 2 diabetic,
smoking, and ischemic heart disease patients reﬂects the
reduced nitric oxide bioavailability, which can be assessed by
diﬀerent methods [98]. Patients with chronic heart failure
did not show a signiﬁcant eﬀect in response to the NOS
inhibitorNG-methyl-L-argininesuggestingthatNOdoesnot
contribute to basal vascular tone in these individuals. The
responses to nitroglycerin and to serotonin were impaired,
suggesting that there is smooth muscle dysfunction and
endothelial dysfunction in patients with chronic heart failure
[99]. Nitrate tolerance can be seen as an extreme example of
nitrate resistance [100], and is thought, at least in part, to
be secondary to the increased oxidative stress present in the
aforementioneddiseasestates.Thus,clinicalnitratetolerance
and nitrate-induced activation of the renin-angiotensin-
aldosterone system (RAAS) as well as increased oxidant
stress (see Section 2.3) may be regarded as an extension
of the primary pathophysiological phenomenon of nitric
oxide resistance (see Figure 2)[ 100]. Since diabetes is also
associated with severe activation of the RAAS (see Section
1.2), the eﬀects of diabetes and nitrate therapy could be
additive and further impair endothelial function as well
as nitrate potency. Hence, the potency of nitrates may be
blunted by an underlying primary NO resistance to give a
“primary” nitrate tolerance [101] whereas the mechanisti-
cally similar “secondary” nitrate tolerance (pseudotolerance)
develops under chronic treatment [102]. These two nitrate
tolerance states can even occur within the same patient.
However, to date, it is not completely clariﬁed whether
pseudotolerance (secondary nitrate tolerance) contributes
to endothelial dysfunction in response to an impaired NO
responsiveness (NO resistance). However, evidence support-
ing this notion comes from a multivariate analysis of two
observational coronary secondary prevention studies which
showed increased mortality in chronically nitrate-treated
ischemic heart disease patients following recovery from an
acute cardiac event [94]. Also, a randomized controlled trial
was performed and showed that continuous nitroglycerin
treatment leads to endothelial dysfunction in both ischemic
heart disease patients [103] and healthy volunteers [104].
In a series of experiments, impaired vasodilator responses
to nitroglycerin were demonstrated in patients with diabetes
mellitus when compared with age and sex matched controls
[105, 106].
These impaired responses were somewhat surprising
since nitrate-induced vasodilation has been shown to be
increased when the endothelium is damaged and diabetes
is associated with impaired endothelial function [9]. A
possible explanation may be that the biotransformation of
organic nitrates requires intracellular sulfhydryl groups in
order to produce vasoactive intermediates [107]. Oxidative
depletion of these sulfhydryl donors will cause impaired
responsiveness to organic nitrates. In diabetes antioxidant
activity is decreased [108]. The increase in oxidative stress
and free radical activity that occurs in diabetes probably
alters the redox equilibrium of intracellular thiols leading to
primary oxidation or depletion of these essential sulfhydryl
donors. But also succination of thiols may contribute to
decreasedsulfhydrylconcentration[109].Depletionofthiols
is also envisaged in rats with streptozotocin-induced exper-
imental diabetes that have signiﬁcantly decreased serum
antioxidant capacity (which largely depends on serum thiol
groups) (unpublished observations, Oelze and Daiber).
This is one possible explanation for an impaired nitrate
response observed in diabetes [102, 105]. According to the
recent development in the nitrate ﬁeld, the mitochondrial
nitrate reductase ALDH-2 could play a role as well. This
enzyme requires dithiols (e.g.,dihydrolipoic acid) in orderto
bioactivate nitroglycerin or PETN [43] and depletion of the
pool of reduced thiols would probably lead to impairment of
enzymatic activity. Although PETN also requires dithiols for
bioactivation, this organic nitrate has slow pharmacokinetics
preventing an overcharge of the bioactivating capacity of the
organism[74,110].Thishypothesisisinaccordancewiththe
recent observation that ALDH-2 activity is decreased in the
testis of diabetic animals [111] although this observations
needs further animal experimental or clinical veriﬁcation
in vascular tissue. Vice versa, inactivation of ALDH-2 by
nitroglycerin was demonstrated to increase the infarct area
in experimental MI [78] and ALDH-2 activation is related
to PKCε [112]. Recently, Ma et al. have demonstrated that
ALDH-2 knockout aggravated, and ALDH-2 overexpression
improved, ischemic damage in response to experimental
MI [113]. Interestingly, these authors revealed a correlation
betweenALDH-2andAMP-activatedkinase(AMPK),which
is an important metabolic enzyme involved in the manage-
ment of disease states such as diabetes [114–116]. Besides
the loss of AMPK activity by GTN-induced inactivation of
ALDH-2, diabetic complications could be further aggravated
by impaired breakdown of toxic aldehydes—it may be
speculated that inhibition of ALDH-2 and AMPK may
contribute to increased mortality of diabetic patients. In
conclusion, for patients with congestive cardiac failure, type
II diabetes and acute myocardial infarction resistance to the
action of organic nitrates was demonstrated. In addition,
thereisgoodevidencethatasigniﬁcantpercentageofnormal
subjects have impaired organic nitrate vasodilator potency
[117].
3.2. Eﬀectiveness of Antioxidants in Diabetes- and Nitrate-
Associated Vascular Complications. It was previously shown
for the setting of nitrate tolerance and diabetes that there
is increased formation of reactive oxygen species and/or
decreased breakdown of those species leading to oxidative
stress [2, 3, 66, 82]. Accordingly, there is a large number
of studies demonstrating that cotreatment with antioxidants
ameliorates nitrate- and diabetes-induced vascular oxidative
stress and dysfunction. Examples include the use of direct
antioxidants such as hydralazine [62, 93], vitamin C [40],
superoxide dismutase [82], N-acetylcysteine [118], ebselen
[84], and drugs with indirect antioxidant properties such as
statins [119], AT1-receptor antagonists [59], ACE inhibitors
[52], and the β-blocker carvedilol [120] (more compounds
are reviewed in [32]). The antioxidant lipoic acid couldExperimental Diabetes Research 7
improve nitrate tolerance which could be partially due to
the fact that lipoic acid is the reducing cofactor of the
nitratebioactivatingenzymeALDH-2[43,74,121].Itshould
be also noted that NO itself is a highly potent superoxide
scavenger, although the resulting formation of peroxynitrite
may limit the importance of this antioxidant property.
Accordingly, organic nitrates with high turnover to NO may
provide intrinsic antioxidant eﬀects. The important role
of oxidative stress for the development and progression of
nitrate tolerance was further supported at a molecular level
by the observation that vascular dysfunction in response to
nitroglycerinwasimprovedbygeneticdeletionofp47phox,an
essential subunit of the superoxide generating NADPH oxi-
dase (Nox2) [87]. In contrast, genetic deletion of the impor-
tant mitochondrial antioxidant protein manganese superox-
ide dismutase (MnSOD) caused an additional aggravation
of nitrate-induced vascular dysfunction [83]. Interestingly,
diabetes shows a very similar responsiveness to antioxidant
treatment indicating that similar mechanisms as in nitrate
tolerance account for vascular complications in diabetic
patients and animals (see the aforementioned triggers for
nitrate resistance and endothelial dysfunction). Improve-
ment of vascular dysfunction and oxidative stress in diabetes
was shown for direct antioxidants such as vitamin C [122,
123], lipoic acid [28, 124], ebselen [25], N-acetylcysteine
[125],glutathione [126],anddrugswithindirectantioxidant
properties such as statins [127], AT1-receptor antagonists, or
ACE inhibitors [8, 21, 128]. It should be noted that vitamin
C was infused at high doses whereas oral administration
did not improve endothelial dysfunction in diabetic patients
[129] and even increased mortality in diabetic women [130].
Further evidence for an important role of oxidative stress
for diabetic complications was provided at a molecular level
by demonstrating that oxidative modiﬁcations contributing
to diabetic retinopathy were prevented by overexpression of
the MnSOD in a transgenic mouse model [131]. Likewise
cardiomyocytefunctionandoxidativestresswerebeneﬁcially
inﬂuenced by overexpression of catalase in experimental
models of type 1 and 2 diabetes [29]. Based on these data,
there are striking parallels between nitrate tolerance and
diabetes mellitus that converge at the level of oxidative
stress as well as vascular dysfunction, which may explain
nitrate resistance in the setting of diabetes. In accordance
with these considerations, the clinical study of Picano and
coworkers demonstrated that diabetes and nitrate therapy
evoke synergistic oxidative DNA damage [132] suggesting
that the pathophysiological mechanisms are similar in
the setting of diabetes and nitrate tolerance. Comparable
observations were made in atherosclerotic rabbits where
nitroglycerin treatment synergistically increased the protein
tyrosine nitration (a marker for peroxynitrite formation) in
hyperlipidemic animals [133].
3.3. Is Diabetes Mellitus Another Battleﬁeld for Pentaerithrityl
Tetranitrate? As discussed above, the use of organic nitrates
in diabetic patients is associated with certain risks: besides
reduced eﬃcacy of the drugs due to nitrate resistance in
these individuals, there might be synergistic damage to the
vascular system since nitrate treatment and diabetes both
are associated with oxidative complications. Since PETN
is devoid of tolerance [67], oxidative stress [71]a n de v e n
normalizedvascularfunctioninexperimentalatherosclerosis
[134], it might be expected that this nitrate demonstrates
beneﬁcial eﬀects in the setting of diabetes. Considering
the mechanisms underlying the protective eﬀects of PETN,
mainly based on induction of HO-1 [77], ferritin [135],
ecSOD [95], and other protective genes/proteins [75]a s
discussed afore (summarized in Figure 1), PETN indeed
could be a suitable nitrate for treatment of ischemia in
diabeticpatients.Hemeoxygenase-1inductionbyheminwas
also able to suppress nitroglycerin-induced tolerance [77].
Of note are the observations that induction heme oxygenase
lead to increased expression of ecSOD [31], and pharmaco-
logical as well as genetic overexpression of heme oxygenase
protects from diabetic cardiovascular complications [31,
136] (summarized in Figure 1), whereas genetic deﬁciency
in HO-1 aggravates myocardial ischemia/reperfusion injury
in diabetic mice [137]. Therefore, it may be speculated that
PETN-induced heme oxygenase-1 and ecSOD induction are
able to improve vascular function, redox state and even
prognosisindiabeticpatients.Accordingtoanongoingstudy
in our laboratory, PETN, in contrast to ISMN, is able to
improve vascular complications in experimental diabetes.
PETN corrected endothelial dysfunction by approximately
50% and improved nitrate resistance almost completely
whereas ISMN had only minor eﬀects on vascular dysfunc-
tion. Vascular and cardiac mitochondrial ROS formation as
well as cardiac NADPH oxidase and serum xanthine oxidase
activities were signiﬁcantly improved by PETN whereas
ISMN even increased NADPH oxidase activity. There is
also evidence that PETN improves eNOS function and
normalizes endothelial dysfunction in experimental diabetes
via restoration of tetrahydrobiopterin levels, probably by
preventing oxidative depletion of BH4 and upregulation of
GTP-cyclohydrolase, the BH4 synthesizing enzyme. These
beneﬁcial eﬀects of PETN on eNOS function, NADPH
oxidase activity, and oxidative stress have recently been
demonstrated for experimental hypertension in angiotensin-
II infused rats [138]. To our best knowledge, this was the
ﬁrst report on the improvement of angiotensin-II-induced
hypertension by an organic nitrate.
4. Conclusion and Clinical Implications
The endothelium plays a pivotal role in modulating the
reactivity of vascular smooth muscle through the formation
of several vasoactive substances. There is good evidence
for endothelial and smooth muscle dysfunction in dia-
betes which is shared by the pharmacologically-induced
phenomenon of nitrate tolerance. Oxidative stress plays an
important role in the setting of both vascular complications
and may explain the presence of nitrate resistance in diabetic
vessels, a major drawback for the use of nitrates in diabetic
patients. Since nitrate tolerance as well as diabetes-associated
vascular dysfunction nicely respond to antioxidant treat-
ment, this may be the key to improve the safety and eﬃcacy
of a given organic nitrate in diabetic patients. One strategy
could be a combination therapy of an antioxidant (e.g.,8 Experimental Diabetes Research
hydralazine or lipoic acid) for which a relief of nitrate tol-
erance has been previously demonstrated. The combination
of ISDN and hydralazine improved the eﬃcacy of the nitrate
dramatically in black patients with heart failure. Another
promisingattemptwouldbetheuseofpentaerithrityltetran-
itrate which is devoid of nitrate tolerance and oxidative stress
due to induction of antioxidant pathways (e.g., HO-1 and
ecSOD). It remains to be established whether these highly
promising observations, that are mainly based on animal
experimental data, maybetranslated to theclinical situation.
First evidence for beneﬁcial eﬀects of PETN treatment in
diabetic patients comes from a cost comparison analysis
contrasting PETN and ISDN prescribed to diabetic patients
in primary care practices in Germany [139]. PETN therapy
tended to produce a saving in costs compared to ISDN
therapy in diabetic patients when costs for comedication
were taken into account and after adjustment for age and
comorbidity. Future eﬀort may also be directed towards
the development of new organic nitrates that are devoid
of tolerance and oxidative stress. A promising strategy is
the synthesis of hybrid molecules by introduction of a
nitrate function into established cardiovascular drugs such
as AT1-receptor blockers or glitazones (both drug classes
have been demonstrated to prevent the development of
nitrate tolerance). These compounds not only could possess
intrinsic antioxidant eﬀects, but also provide synergistic
antihypertensive, antihyperglycemic, and antiatherosclerotic
eﬀects.
Glossary
Clinical nitrate tolerance: impaired vasodilatory potential of
a given organic nitrate in response to chronic use of the
drug (may comprise of “pseudotolerance,” “NO resistance,”
“endothelial dysfunction” and impaired nitrate bioactiva-
tion).
Nitrate tachyphylaxis: fast onset of in vitro or in vivo
tolerance due to high-dose acute treatment with an organic
nitrate (most probably comprises of impaired nitrate bioac-
tivation).
Primary tolerance: resistance of the vasculature to
endogenous and/or exogenous vasodilators encountered in
certainpathophysiologicalstatessuchasdiabetesorcoronary
artery disease. This primary tolerance may be directed to
organic nitrates termed “nitrate resistance” or to other NO
donors as well as endogenous NO formation termed “NO
resistance.”
Secondary tolerance: resistance of the vasculature to
exogenousvasodilatorsencounteredafterprolonged(clinical
tolerance) or high-dose (tachyphylaxis) use of these drugs.
This secondary tolerance may be directed to organic nitrates
termed “nitrate tolerance” or to other vasodilators generally
termed “desensitization.”
Pseudotolerance: loss of vasodilatory potential of a given
drug due to humoral counterregulation (e.g., activation of
the RAAS). Pseudotolerance is closely correlated with the
“rebound phenomenon” upon withdrawal of the drug.
NO resistance: inadequate vasodilatory response of
the vasculature to exogenous or endogenous nitric oxide
encountered in certain pathophysiological states such as
diabetes or coronary artery disease or upon development of
“secondary tolerance.”
Nitrate resistance: special form of “primary tolerance.”
Inadequate vasodilatory response of the vasculature to
exogenous organic nitrate therapy encountered in certain
pathophysiological states such as diabetes or coronary artery
disease or upon development of “secondary tolerance.”
Endothelial dysfunction: inadequate vasodilatory
response of the vasculature to exogenous or endogenous
endothelium-dependent vasodilators encountered in certain
pathophysiological states such as diabetes or coronary
artery disease or upon chronic use of organic nitrates (e.g.,
“cross-tolerance” to acetylcholine).
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